Vaxart, Inc.

DB:NB11 Stock Report

Market Cap: €130.9m

Vaxart Valuation

Is NB11 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NB11 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NB11's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NB11's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NB11?

Key metric: As NB11 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NB11. This is calculated by dividing NB11's market cap by their current revenue.
What is NB11's PS Ratio?
PS Ratio8.1x
SalesUS$16.76m
Market CapUS$136.30m

Price to Sales Ratio vs Peers

How does NB11's PS Ratio compare to its peers?

The above table shows the PS ratio for NB11 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.9x
2INV 2invest
8.2xn/a€63.8m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
FYB Formycon
13.6x33.4%€827.2m
BIO3 Biotest
1.5x3.6%€1.4b
NB11 Vaxart
8.1x45.2%€136.3m

Price-To-Sales vs Peers: NB11 is good value based on its Price-To-Sales Ratio (8.1x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does NB11's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
NB11 8.1xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NB11 is expensive based on its Price-To-Sales Ratio (8.1x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is NB11's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NB11 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: NB11 is expensive based on its Price-To-Sales Ratio (8.1x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NB11 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.57
€4.56
+698.2%
48.0%€7.55€2.36n/a3
Nov ’25€0.66
€4.38
+564.4%
48.0%€7.26€2.27n/a3
Oct ’25€0.75
€4.38
+486.6%
48.0%€7.26€2.27n/a3
Sep ’25€0.69
€4.38
+538.3%
48.0%€7.26€2.27n/a3
Aug ’25€0.55
€4.91
+795.9%
52.4%€7.47€2.34n/a2
Jul ’25€0.63
€4.91
+678.6%
52.4%€7.47€2.34n/a2
Jun ’25€0.68
€4.62
+580.5%
60.0%€7.39€1.85n/a2
May ’25€0.66
€4.59
+598.5%
60.0%€7.35€1.84n/a2
Apr ’25€1.25
€4.59
+267.4%
60.0%€7.35€1.84n/a2
Mar ’25€1.12
€4.63
+313.4%
60.0%€7.40€1.85n/a2
Feb ’25€1.04
€4.63
+343.0%
60.0%€7.40€1.85n/a2
Jan ’25€0.51
€4.44
+772.7%
68.4%€7.48€1.40n/a2
Dec ’24€0.65
€4.44
+584.7%
68.4%€7.48€1.40n/a2
Nov ’24€0.62
€4.21
+580.8%
59.5%€7.48€1.40€0.663
Oct ’24€0.70
€4.21
+500.0%
59.5%€7.48€1.40€0.753
Sep ’24€0.75
€4.09
+444.9%
59.5%€7.27€1.36€0.693
Aug ’24€0.73
€5.36
+629.2%
59.5%€9.19€1.38€0.553
Jul ’24€0.67
€5.29
+686.6%
59.5%€9.07€1.36€0.633
Jun ’24€1.13
€5.29
+369.2%
59.5%€9.07€1.36€0.683
May ’24€0.70
€5.38
+673.1%
59.5%€9.22€1.38€0.663
Apr ’24€0.71
€5.38
+656.8%
59.5%€9.22€1.38€1.253
Mar ’24€0.74
€6.25
+745.3%
47.5%€9.43€1.42€1.124
Feb ’24€0.97
€6.25
+544.1%
47.5%€9.43€1.42€1.044
Jan ’24€0.90
€6.25
+596.5%
47.5%€9.43€1.42€0.514
Dec ’23€1.12
€7.74
+588.7%
19.1%€9.99€5.99€0.654
Nov ’23€1.67
€7.79
+365.6%
19.1%€10.05€6.03€0.624

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Perrigo

US$3.7b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$25.74

7D

1.9%

1Y

-7.4%

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

7D

6.7%

1Y

3.9%